A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)

NCT02000440 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Glomerulosclerosis, Focal Segmental

Interventions

DRUG: Losmapimod

Sponsor

GlaxoSmithKline